Agios Sustainability Profile
Agios Pharmaceuticals, often referred to simply as Agios, is a prominent biopharmaceutical company headquartered in the United States. Founded in 2008, Agios has established itself as a leader in the field of metabolic oncology, focusing on the discovery and development of innovative therapies for cancer and rare genetic diseases. With a strong emphasis on precision medicine, Agios has made significant strides in developing unique small molecule drugs that target specific metabolic pathways. Their flagship products, including therapies for acute myeloid leukaemia and hereditary cancer syndromes, highlight the company's commitment to addressing unmet medical needs. Recognised for its pioneering research and development efforts, Agios continues to solidify its market position through strategic partnerships and a robust pipeline of potential treatments, making it a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Agios's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Agios's score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Agios's reported carbon emissions
Agios Pharmaceuticals, headquartered in the US, currently does not have any publicly available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The absence of emissions data suggests that the company may not have established measurable climate commitments or reduction strategies at this time. As of now, Agios has not cascaded any emissions data from a parent or related organization, indicating that their climate strategy is independently developed. Without specific figures or targets, it is unclear how Agios plans to address its carbon footprint or contribute to broader climate goals. In the context of the pharmaceutical industry, companies are increasingly expected to set ambitious climate targets and report on their emissions. Agios's current lack of data may reflect an opportunity for future commitment to sustainability and climate action.
How Carbon Intensive is Agios's Industry?
How Carbon Intensive is Agios's Location?
Agios's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Agios has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
